Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NanoSomiX Inc.

www.nanosomix.com

Latest From NanoSomiX Inc.

Alzheimer’s Disease: Moving Toward The Era Of Diagnostic Certainty

With more than 13 million people in the US expected to have Alzheimer’s disease (AD) by 2050, an increasing number of companies are focused on developing reliable AD diagnostics designed to facilitate early detection and treatment. Although the field remains in its relative infancy, researchers are gaining greater diagnostic certainty through a combination of diagnostic approaches, and over the next decade, the AD diagnostics market is projected to reach a US market value of at least $1 billion to $3 billion per year.

Medical Device Innovation

NanoSomiX: Blood Test For Early Alzheimer’s Detection

Envision a simple blood test that can detect the presence of Alzheimer’s disease up to 10 years in advance of a standard clinical diagnosis. NanoSomiX Inc. is developing technology that evaluates brain-derived exosomes and reveals biological changes that are implicated in the pathogenesis of AD.

Medical Device

Start-Up Previews, November 2014

The emerging life sciences companies profiled in the November issue of Start-Up: ImmuneXcite, Inivata, Lumoptik, NanoSomiX, and Scholar Rock.

BioPharmaceutical Medical Device

NanoSomiX Inc.

Envision a simple blood test that can detect the presence of Alzheimer’s disease up to 10 years in advance of a standard clinical diagnosis. NanoSomiX Inc. is developing technology that evaluates brain-derived exosomes and reveals biological changes that are implicated in the pathogenesis of AD.

Medical Device BioPharmaceutical
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • NanoSomiX Inc.
  • Senior Management
  • John Osth, CEO
    Masato Mitsuhashi, PhD, CSO
  • Contact Info
  • NanoSomiX Inc.
    Phone: (949) 215-6808
    27068 La Paz Road
    Ste. 555
    Aliso Viejo, CA 92656
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register